{"brief_title": "Study of TRAVATAN in Subjects With Iris Pigmentation Changes", "brief_summary": "The purpose of this study was to monitor iris pigmentation changes over a 5-year period in patients with open-angle glaucoma or ocular hypertension. To be eligible for the study, these individuals must have experienced an iris pigmentation change while previously dosing with TRAVATAN.", "condition": ["Open-Angle Glaucoma", "Ocular Hypertension"], "intervention_type": ["Drug"], "intervention_name": ["Travoprost, 0.004% ophthalmic solution"], "arm_group_label": ["TRAVATAN"], "other_name": ["TRAVATAN\u00ae"], "study_pop": "\n      ", "sampling_method": "Non-Probability Sample", "criteria": "Inclusion: - \ufeffDiagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension; - Has experienced an iris pigmentation change while dosing with TRAVATAN; - Currently dosing with TRAVATAN; - Other protocol-defined inclusion criteria may apply. Exclusion: - Any form of glaucoma other than open-angle glaucoma (with or without a pigment dispersion or pseudoexfoliation component) or ocular hypertension; - Not currently using TRAVATAN; - Females of childbearing potential if pregnant, breast-feeding, or not using highly effective birth control measures; - History of any severe ocular pathology (including severe dry eye); - Other protocol-defined exclusion criteria may apply.", "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "pigmentation", "mesh_term": ["Hypertension", "Glaucoma", "Glaucoma, Open-Angle", "Ocular Hypertension", "Travoprost", "Ophthalmic Solutions"], "id": "NCT00047554"}